This month, the company reported a 28 percent increase in third-quarter sales compared with the same quarter last year.

Yesterday, the company announced preliminary third-quarter sales and earnings increases of more than 300 percent.

It said third-quarter sales rose 4.8 percent, to $1.59 billion, from $1.52 billion last year.

Reuters also said third-quarter sales rose 16 percent, to $:888 million, or about $1.29 billion.

The shares dropped after the company said third-quarter sales fell 7 percent, to $1.33 billion.

The company also said third-quarter sales were hurt by competition from generic drug makers.

Neupogen's third-quarter sales rose 7 percent, to $230 million worldwide.

It said third-quarter retail sales in the city increased 0.8 percent, compared to the third quarter of 1993.

Over all, Pfizer said its third-quarter sales rose 9 percent, to $12.3 billion.

Based on third-quarter sales last year, the answer is anything digital and portable.